Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 99.191 mg - tablet - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 66.127 mg - tablet - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cinacalcet hydrochloride, quantity: 33.064 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). cinacalcet viatris (cinacalcet hydrochloride tablets) should be used as adjunctive therapy.,cinacalcet viatris (cinacalcet hydrochloride tablets) is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. cinacalcet viatris (cinacalcet hydrochloride tablets) may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)]. limitations of use: cinacalcet hydrochloride tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)]. cinacalcet hydrochloride tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2)] . cinacalcet hydrochloride tablets are indicated for the treatment of severe hypercalcemia in adult patients with primary hpt who are unable to undergo parathyroidectomy [see clinical studies (14.3)] . cinacalcet hydrochloride tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1)]. risk summary limited case reports of cinacalcet hydrochloride tablets use in pregn

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)] . limitations of use: cinacalcet hydrochloride tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)] . cinacalcet hydrochloride tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2)] . cinacalcet hydrochloride tablets are indicated for the treatment of severe hypercalcemia in adult patients with primary hpt who are unable to undergo parathyroidectomy [see clinical studies (14.3)] . cinacalcet treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1)] . risk summary limited case reports of cinacalcet use in pregnant women are insufficient to inform a dr

United States - English - NLM (National Library of Medicine)

cipla usa inc. - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet 30 mg - cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)]. limitations of use: cinacalcet hydrochloride tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)]. cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2)] . cinacalcet hydrochloride tablets are indicated for the treatment of hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. [see clinical studies (14.3)] . cinacalcet hydrochloride tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1)]. risk summary l

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)] . limitations of use: cinacalcet tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)] . cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2) ] . cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy [see clinical studies (14.3)] . cinacalcet hcl treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1) ] . risk summary limited case reports of cinacalcet hcl use in pregn

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 30 mg - calcium homeostasis

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 60 mg - calcium homeostasis

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 90 mg - calcium homeostasis